Lilly's CEO John Lechleiter takes to the bully pulput again to inform the Presidential candidates to not forget the importance of the biopharm industry to a healthy US economy. He wants data exclusivity provisions (similar to US Affordable Care Act) included in the new Trans-Pacific Partnership agreement.
Lechleiter believes TPP is a vital channel to allow US pharma to shine across Asia and its expected large and fast-growing markets. But, investors will only play in supporting this if US IP is protected. With this protection, investors will invest to fuel job growth,help maintain US global leadership and to extend life-saving medicines to the rest of the world. The TPP participants will also be setting the standard that non-participants like China must meet.
If we want to build on the 4 million plus jobs of the US biopharm industry, we need to support it through reasonable IP protection in balance with free trade.
Posted by Bruce Lehr Oct 19th 2012.